Patents by Inventor James A. Tumlin

James A. Tumlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10822295
    Abstract: The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use. Also disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of a menaquinol compound as disclosed above, or a mixture thereof, and a pharmaceutically acceptable excipient, wherein the composition is effective for the treatment of a condition associated with vitamin K selected from for the treatment of osteoporosis and arteriosclerosis.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: November 3, 2020
    Assignee: EPIZON PHARMA, INC.
    Inventors: Keith E. Drouet, James A. Tumlin
  • Publication number: 20200306207
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
  • Publication number: 20200306208
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
  • Publication number: 20200306206
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
  • Patent number: 10744101
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: August 18, 2020
    Assignee: Epizon Phama, Inc.
    Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
  • Patent number: 10744102
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: August 18, 2020
    Assignee: Epizon Pharma, Inc.
    Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
  • Patent number: 10736858
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: August 11, 2020
    Assignee: Epizon Pharma, Inc.
    Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
  • Publication number: 20200222337
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.
    Type: Application
    Filed: March 12, 2020
    Publication date: July 16, 2020
    Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
  • Publication number: 20200206159
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.
    Type: Application
    Filed: March 12, 2020
    Publication date: July 2, 2020
    Inventors: JAMES A. TUMLIN, Paul L. Darke, John M. Rudey
  • Publication number: 20200206158
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.
    Type: Application
    Filed: March 12, 2020
    Publication date: July 2, 2020
    Inventors: JAMES A. TUMLIN, Paul L. Darke, John M. Rudey
  • Patent number: 10688064
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: June 23, 2020
    Assignee: Epizon Pharma, Inc.
    Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
  • Publication number: 20200079718
    Abstract: The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use.
    Type: Application
    Filed: September 6, 2019
    Publication date: March 12, 2020
    Applicant: Epizon Pharma, Inc.
    Inventors: Keith E. Drouet, James A. Tumlin
  • Publication number: 20190374483
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 12, 2019
    Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
  • Publication number: 20190374484
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 12, 2019
    Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
  • Publication number: 20190054226
    Abstract: The present disclosure relates to a dialysis apparatus comprising a membrane having at least one protein from the lipocalin family bound thereon. The disclosure further relates to methods of removing non-polar, hydrophobic and/or protein bound uremic toxins from a target subject utilizing the dialysis apparatus described herein as well as methods of extracorporeal detoxification.
    Type: Application
    Filed: May 14, 2018
    Publication date: February 21, 2019
    Inventor: James A. Tumlin
  • Patent number: 9968722
    Abstract: The present disclosure relates to a dialysis apparatus comprising a membrane having at least one protein from the lipocalin family bound thereon. The disclosure further relates to methods of removing non-polar, hydrophobic and/or protein bound uremic toxins from a target subject utilizing the dialysis apparatus described herein as well as methods of extracorporeal detoxification.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: May 15, 2018
    Assignee: NephroGenesis LLC
    Inventor: James A. Tumlin
  • Publication number: 20170360732
    Abstract: The present disclosure relates to a method of maintaining luminal patency of a blood vessel following vessel injury, the method including administering a composition comprising at least one lysyl oxidase inhibitor and D-penicillamine to a subject in need thereof Compositions to support the methods are also provided.
    Type: Application
    Filed: December 8, 2015
    Publication date: December 21, 2017
    Inventor: James A. Tumlin
  • Publication number: 20150290381
    Abstract: The present disclosure relates to a dialysis apparatus comprising a membrane having at least one protein from the lipocalin family bound thereon. The disclosure further relates to methods of removing non-polar, hydrophobic and/or protein bound uremic toxins from a target subject utilizing the dialysis apparatus described herein as well as methods of extracorporeal detoxification.
    Type: Application
    Filed: June 12, 2015
    Publication date: October 15, 2015
    Inventor: James A. Tumlin
  • Patent number: 8546095
    Abstract: The methods of the disclosure provide fluorescence-based assays for calcineurin activity, especially in isolated T cells. The methods include the stimulation of the T cells with agents that specifically target the TCR with or without influencing co-stimulatory pathways. One TCR agonist is monoclonal antibodies specific for CD3, which more precisely distinguish the inducible activity of calcineurin than does an alternative method targeting the T cell receptor (CD3) combined with CD28 costimulation. This method more accurately distinguishes between the measured level of calcineurin activity of T cells from immunosuppressed transplant recipients and normal individuals, and thus has improved diagnostic accuracy with respect to the response of an individual to immunosuppressant therapy following an organ transplant.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: October 1, 2013
    Assignee: Emory University
    Inventors: James Tumlin, Allan D. Kirk, Brian R. Roberts, Jennifer Gooch
  • Publication number: 20130115640
    Abstract: Provided herein are methods for prophylactic treatment of Diabetes Mellitus comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual suspected of having, predisposed to, or at risk of developing Diabetes Mellitus. Also provided herein are methods for monitoring treatment of Diabetes Mellitus by measuring and monitoring levels of MCP-1, TGF-?, VEGF A and VEGF B.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 9, 2013
    Inventors: James A. Tumlin, Claude Galphin, Brad Rovin